Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice

Advances in Therapy

Volumn 27, Issue 3, 2010, Pages 181-191

  Menown, Ian ^a   Montalescot, Gilles ^b   Pal, Nikhal ^a   Fidler, Carrie ^c   Orme, Michelle ^c   Gillard, Samantha ^c  

^a Craigavon Cardiac Centre   (United Kingdom)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Decision Resources Group   (United Kingdom)

Author keywords

Cost benefit analysis; Enoxaparin; Myocardial infarction; Unfractionated heparin

Indexed keywords

ENOXAPARIN; HEPARIN; THROMBOPLASTIN;

ARTICLE; BLEEDING; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION TREE; DRUG COST; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; HUMAN; PARTIAL THROMBOPLASTIN TIME; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; TREATMENT DURATION;

COST-BENEFIT ANALYSIS; DECISION TREES; ELECTROCARDIOGRAPHY; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MARKOV CHAINS; MYOCARDIAL INFARCTION; QUALITY-ADJUSTED LIFE YEARS;

EID: 77952986995     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0013-x     Document Type: Article

References (32)

1. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909- 2945.
2. Betriu A, Masotti M. Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis. Am J Cardiol. 2005;95:100-101.
3. Danchin N, Coste P, Ferrières J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the French Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI). Circulation. 2008;118:268- 276.
4. Armstrong PW, WEST Steering Committee. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early STelevation myocardial infarction Therapy) study. Eur Heart J. 2006;27:1530-1538.
5. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation. 2008;117:296- 329.
6. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
7. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with frontloaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716-722.
8. White H. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001;358:1855-1863.
9. Antman EM. The search for replacements for unfractionated heparin. Circulation. 2001;103:2310-2314.
10. Menown IBA. New anticoagulant strategies In ST-elevation myocardial infarction treated with fibrinolytic therapy. Br J Cardiol. 2008:15:87-94.
11. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477-1488.
12. Montalescot G, Philippe F, Ankri A, et al. for the French Investigators of the ESSENCE trial. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation. 1998;98:294-299.
13. Antman EM, Handin R. Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation. 1998;98:287-289.
14. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IBA, Yusuf S. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction. A meta-analysis of the randomized trials. Circulation. 2005;112:3855-3867.
15. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J. 2007;28:2077-2086.
16. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114:774-782.
17. Carruthers KF, Dabbous OH, Flather MD, et al. Contemporary management of acute coronary syndromes: does the practice match the evidence? The global registry of acute coronary events (GRACE). Heart. 2005;91:290-298.
18. Robinson M, Palmer S, Sculpher M, et al. Costeffectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling. Health Technol Assess. 2005;9:1-158.
19. Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics. 2003;21(suppl. 1):43-50.
20. HM Treasury. Green Book: Appraisal and evaluation in central government. 2003. Available at: www.hm-treasury.gov.uk/d/green-book-complete.pdf. Accessed June 1, 2008.
21. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009;30:1457-1466.
22. British National Formulary website. BNF 55. Available at: www.bnf.org.uk Accessed May 1, 2008.
23. Newcastle Upon Tyne NHS Trust. Newcastle Upon Tyne Hospital NHS Trust Provider Tariff 2005/6 - Haematology. Newcastle Upon Tyne: NHS; 2006.
24. Nicholson T, McGuire A, Milne R. Cost-utility of enoxaparin compared with unfractionated heparin in unstable coronary artery disease. BMC Cardiovasc Disord. 2001;1:2.
25. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43:736-749.
26. Tengs TO, Lin TH. A meta-analysis of quality-oflife estimates for stroke. Pharmacoeconomics. 2003;21:191-200.
27. Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med. 1995;10:321-330.
28. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Available at: www.york.ac.uk/inst/che/pdf/DP172.pdf 1999. Accessed June 1, 2008.
29. Steg PG, Goldberg RJ, Gore JM, et al. Baseline characteristics, management practices, and inhospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 2002;90:358-363.
30. Detournay B, Huet X, Fagnani F, Montalescot G. Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French substudy of the ESSENCE trial. Pharmacoeconomics. 2000;18:83-89.
31. Marcoff L, Zhang Z, Zhang W, et al. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment- Thrombolysis In Myocardial Infarction 25) study. J Am Coll Cardiol. 2009;54:1271-1279.
32. Welsh RC, Sauriol L, Zhang Z, Kolm P, Weintraub WS, Theroux P. Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment - Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial. Can J Cardiol. 2009;25:e399-405.